TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22141461

Group type: EXPERIMENTAL
Intervention: Presentation mode showing wayfinding information from eye-level
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Presentation modes showing wayfinding information included in views providing comprehensive configural information
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Presentation mode which always showed north on top of the device
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Presentation mode which rotated according to the orientation of the user
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Both presentation modes based on map fragments
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Individual differences in visual-spatial working memory capacity
Number of subjects: 132
Study: 20605301

Group type: EXPERIMENTAL
Intervention: Serum bicarbonate quartile 1
Number of subjects: 839

Group type: COMPARATOR
Intervention: Serum bicarbonate quartile 4
Number of subjects: 839
Study: 19197198

Group type: EXPERIMENTAL
Intervention: Increased resistance in the squat exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: No increase in resistance in the squat exercise
Number of subjects: 10
Study: 16170936

Group type: EXPERIMENTAL
Intervention: Modified flicker technique with 5 or 8 seconds time constraints
Number of subjects: 62
Study: 12241713

Group type: EXPERIMENTAL
Intervention: Bone marrow‐mononuclear cells
Number of subjects: 45

Group type: COMPARATOR
Intervention: Peripheral blood‐mononuclear cells
Number of subjects: 45
Study: 10403615

Group type: EXPERIMENTAL
Intervention: 10 mg sinitrodil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg sinitrodil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg sinitrodil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7636779

Group type: EXPERIMENTAL
Intervention: Psychosocial factors (state anxiety, avoidance coping, anger held in)
Number of subjects: 186
Study: 1851709

Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy (EIS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 70
Study: 7016628

Group type: EXPERIMENTAL
Intervention: Lactose-free soy isolate formula (Isomil)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard cow's milk-based formula
Number of subjects: 112
Study: 31570246

Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiation therapy (CRT)
Number of subjects: 4347

Group type: COMPARATOR
Intervention: Postoperative chemotherapy alone
Number of subjects: 4347

Group type: EXPERIMENTAL
Intervention: Postoperative CRT
Number of subjects: 4347
Study: 31226443

Group type: EXPERIMENTAL
Intervention: In-depth, individualized RT plan review during week 1 of RT (Arm B)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard nondetailed review (Arm A)
Number of subjects: 64
Study: 28506550

Group type: EXPERIMENTAL
Intervention: Intra‐ and postoperative sevoflurane (SS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intraoperative sevoflurane and postoperative propofol (SP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intra‐ and postoperative propofol (PP)
Number of subjects: 90
Study: 25856039

Group type: EXPERIMENTAL
Intervention: CNS-led BSE education with additional written BSE instructions
Number of subjects: 37

Group type: COMPARATOR
Intervention: CNS-led BSE education without additional written BSE instructions
Number of subjects: 37
Study: 23968769

Group type: EXPERIMENTAL
Intervention: rWN/DEN4Δ30 vaccine at 10³ PFU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rWN/DEN4Δ30 vaccine at 10⁴ PFU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rWN/DEN4Δ30 vaccine at 10⁵ PFU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rWN/DEN4Δ30 vaccine at 10⁵ PFU (second dose)
Number of subjects: 0
Study: 22068922

Group type: EXPERIMENTAL
Intervention: Rivastigmine patch (9.5 mg/24 h)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Rivastigmine patch (17.4 mg/24 h)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Rivastigmine capsule (12 mg/day)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1050
Study: 19916253

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (US)
Number of subjects: 83
Study: 15668708

Group type: EXPERIMENTAL
Intervention: A ‐‐> CMF
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: GT after chemotherapy
Number of subjects: 466

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 466

Group type: COMPARATOR
Intervention: CMF followed by GT
Number of subjects: 466
Study: 11805748

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 28

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 28
Study: 10076616

Group type: EXPERIMENTAL
Intervention: Human fibrin glue (HFG) used during hernia repair (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group without HFG (group B)
Number of subjects: 50
Study: 8750368

Group type: EXPERIMENTAL
Intervention: 100 mg intravenous lamivudine (administered over 1 hour)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg oral lamivudine (1 mg/mL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg capsule
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg tablet
Number of subjects: 12

Group type: COMPARATOR
Intervention: All oral formulations (oral solution, capsule, tablet)
Number of subjects: 12
Study: 2040325

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 75 mg daily
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 7034454

Group type: EXPERIMENTAL
Intervention: timolol 0.5%
Number of subjects: 19

Group type: COMPARATOR
Intervention: metoprolol 3%
Number of subjects: 19
Study: 31715272

Group type: EXPERIMENTAL
Intervention: Multiplex PCR
Number of subjects: 582

Group type: COMPARATOR
Intervention: Urine culture
Number of subjects: 582
Study: 30274727

Group type: EXPERIMENTAL
Intervention: PSE intervention lessons taught by paraprofessional educators
Number of subjects: 312

Group type: COMPARATOR
Intervention: Nutrition curriculum delivered by classroom teachers
Number of subjects: 312
Study: 27935458

Group type: EXPERIMENTAL
Intervention: Group session of hypnosis with a hypnotic induction (n = 84)
Number of subjects: 167

Group type: COMPARATOR
Intervention: No-induction group receiving identical suggestions without a hypnotic induction (n = 83)
Number of subjects: 167
Study: 25975632

Group type: EXPERIMENTAL
Intervention: Bev+D‐FEC
Number of subjects: 800

Group type: COMPARATOR
Intervention: D‐FEC
Number of subjects: 800
Study: 23359433

Group type: EXPERIMENTAL
Intervention: Adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO)
Number of subjects: 0
Study: 20012308

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg daily for 6 months
Number of subjects: 85
Study: 18762289

Group type: EXPERIMENTAL
Intervention: Global property resemblance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Classifier representing global properties
Number of subjects: 0

Group type: COMPARATOR
Intervention: Models representing scene object information
Number of subjects: 0
Study: 17531764

Group type: EXPERIMENTAL
Intervention: HPV-16/18 L1 VLP AS04 vaccine administered at months 0, 1, and 6
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: HPV-16/18 L1 VLP AS04 vaccine
Number of subjects: 773
Study: 15663340

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (ethinylestradiol/drospirenone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (ethinylestradiol/cyproterone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (ethinylestradiol/desogestrel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (ethinylestradiol/gestodene)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (ethinylestradiol/chlormadinone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (ethinylestradiol/levonorgestrel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (ethinylestradiol/norethindrone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (ethinylestradiol/norgestimate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11680569

Group type: EXPERIMENTAL
Intervention: Thymoglobulin (rabbit anti‐thymocyte globulin), 1.5 mg/kg/day for 6‐14 days
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Thymoglobulin (rabbit anti‐thymocyte globulin)
Number of subjects: 79
Study: 9477711

Group type: EXPERIMENTAL
Intervention: Consolidated Standards for Preparation of Controlled Clinical Trials (CONSORT) checklist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delphi process
Number of subjects: 0
Study: 7861706

Group type: EXPERIMENTAL
Intervention: Chronic higher sodium intake
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Before angiotensin infusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: During angiotensin infusion
Number of subjects: 21
Study: 2910264

Group type: EXPERIMENTAL
Intervention: Mental effort to increase right patellar reflex
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mental effort to increase right patellar reflex and decrease left
Number of subjects: 48

Group type: COMPARATOR
Intervention: Mental effort to increase either right or left knee jerk
Number of subjects: 48
Study: 45587

Group type: EXPERIMENTAL
Intervention: Floctafenine 200 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Dihydrocodeine 60 mg
Number of subjects: 72
Study: 31940670

Group type: EXPERIMENTAL
Intervention: Patient Safety Dashboard
Number of subjects: 12
Study: 31756207

Group type: EXPERIMENTAL
Intervention: Dialogic Reading Group (DRG, n = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Screen Story Group (SSG, n = 16)
Number of subjects: 32
Study: 28231290

Group type: EXPERIMENTAL
Intervention: Descriptive sensory evaluation of apple cultivars
Number of subjects: 85
Study: 26178501

Group type: EXPERIMENTAL
Intervention: Intensive glucose control (stable blood glucose at 6.1‐8.3 mmol/L)
Number of subjects: 72
Study: 23201367

Group type: EXPERIMENTAL
Intervention: Strong placebo treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weak placebo treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatments (both strong and weak)
Number of subjects: 0
Study: 21694454

Group type: EXPERIMENTAL
Intervention: Transdermal 17‐β estradiol (unopposed and opposed with medroxyprogesterone) for 12 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 43
Study: 18435322

Group type: EXPERIMENTAL
Intervention: Obstetric 'skills and drills' training
Number of subjects: 0
Study: 16148997

Group type: EXPERIMENTAL
Intervention: Multiple cancer group (MCG)
Number of subjects: 1125

Group type: COMPARATOR
Intervention: Single cancer group (SCG)
Number of subjects: 1125
Study: 11822980

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phytoestrogens and selective estrogen receptor modulators
Number of subjects: 0
Study: 9442338

Group type: COMPARATOR
Intervention: (-)-3PPP, 300 mg B.I.D. in early efficacy study
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: (-)-3PPP in both studies
Number of subjects: 19
Study: 7557275

Group type: EXPERIMENTAL
Intervention: SMS 201-995
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (50 patients)
Number of subjects: 19
Study: 2643894

Group type: EXPERIMENTAL
Intervention: Droperidol, 0.075 mg/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lidocaine, 1.5 mg/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combination of lidocaine, 1.5 mg/kg and droperidol, 0.025 mg/kg
Number of subjects: 150
Study: 128907

Group type: EXPERIMENTAL
Intervention: Nurse protocol group
Number of subjects: 419

Group type: COMPARATOR
Intervention: Control group (managed by physicians)
Number of subjects: 419
Study: 29949407

Group type: EXPERIMENTAL
Intervention: High dietary sodium (300 mmol/day, 7 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low dietary sodium (20 mmol/day, 7 days)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acute intravenous hypertonic saline infusion (HSI)
Number of subjects: 14
Study: 27060853

Group type: EXPERIMENTAL
Intervention: Sertraline/Olanzapine combination treatment
Number of subjects: 87
Study: 25504098

Group type: EXPERIMENTAL
Intervention: Unilateral percutaneous kyphoplasty (PKP)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Bilateral percutaneous kyphoplasty (PKP)
Number of subjects: 316
Study: 23363721

Group type: EXPERIMENTAL
Intervention: Domestic hydrochloric trimetazidine capsules
Number of subjects: 24

Group type: COMPARATOR
Intervention: Imported hydrochloric trimetazidine tablets
Number of subjects: 24
Study: 20051219

Group type: EXPERIMENTAL
Intervention: Active 20 Hz rTMS of the right DLPFC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Active 20 Hz rTMS of the left DLPFC
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 30
Study: 18310598

Group type: EXPERIMENTAL
Intervention: Individual feedback on performance
Number of subjects: 130

Group type: COMPARATOR
Intervention: Group feedback
Number of subjects: 130
Study: 15841592

Group type: EXPERIMENTAL
Intervention: 4% carbohydrate drink (low concentration)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 11% carbohydrate drink (high concentration)
Number of subjects: 8
Study: 12218773

Group type: EXPERIMENTAL
Intervention: 10 dollars cash incentive
Number of subjects: 1200

Group type: COMPARATOR
Intervention: 5 dollars cash incentive
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Mint candy included
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Large envelope used
Number of subjects: 1200
Study: 9802745

Group type: EXPERIMENTAL
Intervention: GLP‐1 (1.2 pmol x kg(‐1) x min(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (NaCl with 1% human serum albumin)
Number of subjects: 10
Study: 8002198

Group type: EXPERIMENTAL
Intervention: Survey questionnaire utilizing a 30-day recall period with the combination of cough, fast breathing or shortness of breath, and fever.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survey questionnaire with a 15-day recall period.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survey questionnaire with a 30-day recall period.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survey questionnaire in a trained population under surveillance.
Number of subjects: 0
Study: 2524749

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (Surgam)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30033645

Group type: EXPERIMENTAL
Intervention: Ginger root supplement (60 mg of active gingerols/day, four capsules)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 28832589

Group type: EXPERIMENTAL
Intervention: Multimodal counseling program focused on nuisance bleedings
Number of subjects: 448

Group type: COMPARATOR
Intervention: Usual discharge process (control arm)
Number of subjects: 448
Study: 25801058

Group type: COMPARATOR
Intervention: Simvastatin 20 mg alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tong Xin Luo + Simvastatin 20 mg (after 7 days of TCM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nao Xin Tong + Simvastatin 20 mg (after 7 days of TCM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guan Mai Ning + Simvastatin 20 mg (after 7 days of TCM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yin Xing Ye + Simvastatin 20 mg (after 7 days of TCM)
Number of subjects: 0
Study: 23969508

Group type: EXPERIMENTAL
Intervention: Guideline for occupational physicians (OPs)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 524
Study: 21838852

Group type: EXPERIMENTAL
Intervention: High-dose citalopram
Number of subjects: 0
Study: 19145455

Group type: EXPERIMENTAL
Intervention: Plant sterol intake (3.3 g/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Typical American diet
Number of subjects: 22

Group type: COMPARATOR
Intervention: Step 1 diet
Number of subjects: 22
Study: 17925563

Group type: EXPERIMENTAL
Intervention: Cisplatin (60 mg/m2) plus gemcitabine (1,000 mg/m2)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Cisplatin (40 mg/m2) plus vinorelbine (25 mg/m2)
Number of subjects: 159
Study: 14963675

Group type: EXPERIMENTAL
Intervention: 0.4 mg cerivastatin
Number of subjects: 15
Study: 11712610

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ergonomic intervention measures
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Exercises
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Spinal manipulation combined with soft tissue therapy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 15
Study: 9759415

Group type: EXPERIMENTAL
Intervention: HSM IOL (group I)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Foldable acrylic IOL (group II)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Foldable three-piece silicone (group III)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Foldable single-piece silicone (group IV)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: PMMA group (part of group I)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Silicone monobloc group (part of group IV)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Acrylic group (part of group II)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Silicone three-piece group (part of group III)
Number of subjects: 157
Study: 7822584

Group type: EXPERIMENTAL
Intervention: Cue exposure with smoking cues during deprivation (12 hr)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cue exposure with smoking cues during non-deprivation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control cues during deprivation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control cues during non-deprivation
Number of subjects: 0
Study: 30213365

Group type: EXPERIMENTAL
Intervention: 10 mg morphine added to PMDI (Group A)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 0.1 mg morphine added to spinal anesthesia (Group B)
Number of subjects: 97

Group type: COMPARATOR
Intervention: No morphine added (Group C)
Number of subjects: 97
Study: 27481311

Group type: EXPERIMENTAL
Intervention: GI PROMIS measures
Number of subjects: 371

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 371
Study: 24444113

Group type: EXPERIMENTAL
Intervention: Patient-specific reminders shown to healthcare professionals (HCP) in the intervention group.
Number of subjects: 13588

Group type: COMPARATOR
Intervention: Control group with no reminders shown to HCP.
Number of subjects: 13588

Group type: EXPERIMENTAL
Intervention: Patient-specific reminders shown to HCP in the intervention group (follow-up over 6 months).
Number of subjects: 13588

Group type: COMPARATOR
Intervention: Control group with no reminders shown to HCP (follow-up over 6 months).
Number of subjects: 13588
Study: 21277694

Group type: EXPERIMENTAL
Intervention: Adherence to protocol specified radiation therapy guidelines (PP)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Non-adherence to protocol specified radiation therapy guidelines (<PP)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Gemcitabine treatment
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Gemcitabine treatment with adherence to RT guidelines (PP)
Number of subjects: 416
Study: 20135601

Group type: EXPERIMENTAL
Intervention: E-learning software training for 4-6 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional learning material
Number of subjects: 20
Study: 18307372

Group type: EXPERIMENTAL
Intervention: Imipenem administration in healthy volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipenem administration in critical care patients
Number of subjects: 0
Study: 16575033

Group type: EXPERIMENTAL
Intervention: Remifentanil (Group R) - basal infusion of 0.02-0.04 microg x kg(‐1) x min(‐1) with self-administered bolus doses of 0.3 microg x kg(‐1) i.v. every minute as required.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol (Group P) - initial plasma target concentration set at 3-4 microg x mL(‐1).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Remifentanil and Propofol)
Number of subjects: 40
Study: 12679757

Group type: EXPERIMENTAL
Intervention: Oral glycoprotein IIb/IIIa antagonist orbofiban plus aspirin
Number of subjects: 10281

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 10281
Study: 11294060

Group type: EXPERIMENTAL
Intervention: Amisulpride (300 mg daily)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Amisulpride (400 to 800 mg/day, up to 1,200 mg/day)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 5
Study: 8923094

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 217

Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 217
Study: 1525816

Group type: EXPERIMENTAL
Intervention: Quantitative Coronary Angiography (QCA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Caliper measurements
Number of subjects: 50

Group type: COMPARATOR
Intervention: Visual analysis by independent observers
Number of subjects: 50
Study: 2866133

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg at bedtime
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: famotidine 20 mg b.i.d.
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg b.i.d.
Number of subjects: 224

Group type: COMPARATOR
Intervention: ranitidine 150 mg b.i.d.
Number of subjects: 224
Study: 31761855

Group type: EXPERIMENTAL
Intervention: Three-month education training program for care staff
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual care for care staff
Number of subjects: 119
Study: 29991270

Group type: EXPERIMENTAL
Intervention: Diacutaneous fibrolysis
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham diacutaneous fibrolysis
Number of subjects: 52
Study: 26489989

Group type: EXPERIMENTAL
Intervention: Double-layer unlocked closure technique
Number of subjects: 76

Group type: COMPARATOR
Intervention: Single-layer technique
Number of subjects: 76
Study: 25378974

Group type: EXPERIMENTAL
Intervention: 4 mg pitavastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 mg pravastatin
Number of subjects: 0
Study: 22722481

Group type: EXPERIMENTAL
Intervention: Preoperative administration of tegafur suppositories (group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No preoperative treatment (group B)
Number of subjects: 0